IL-13 can substitute for IL-4 in the generation of dendritic cells for the induction of cytotoxic T lymphocytes and gene therapy

Journal of Immunotherapy

Volumn 22, Issue 3, 1999, Pages 229-236

  Alters, Susan E ^a   Gadea, Jose R ^a   Holm, Bari ^a   Lebkowski, Jane ^a   Philip, Ramila ^a  

^a RPR Gencell   (United States)

Author keywords

Cytokine; Dendritic cell adenovirus; Tumor immunotherapy

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 13; INTERLEUKIN 4; TETANUS TOXOID;

ANTIGEN PRESENTATION; ARTICLE; BREAST CANCER; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MELANOMA; MIXED LYMPHOCYTE REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL DIFFERENTIATION; DENDRITIC CELLS; GENE THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INTERLEUKIN-13; INTERLEUKIN-4; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE CULTURE TEST, MIXED; MELANOMA; NEOPLASM PROTEINS; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032948701     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199905000-00005     Document Type: Article

References (31)

1. Grabbe S, Beissert S, Schwartz T, Granstien RD. Dendritic cells as initiators of tumor immune responses: a possible strategy for immunotherapy? Immunol Today 1995;16:117-21.
2. Austyn JM. New insights into the mobilization and phagocytic activity of dendritic cells. J Exp Med 1996;183:1287-1292.
3. Inab K, Metly P. Crowley MT, Steinman RM. Dendritic cell pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med 1990;172:631-640.
4. Mehta DA, Markowicz S, Engleman E. Generation of antigen specific CD8+ CTLs from native precursors. J Immunol 1994;153:996-1003.
5. Flamand V, Sornasse K, Tielemans K, et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994;24:605-10.
6. Pagli P. Chiodoni C, Rodolfo M. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996;183:317-22.
7. Porgador A, Shyder D, Golboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996;156:2918-26.
8. Mayordomo JI, Zorina T, Storkus W, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nature Med 1995;1:1297-302.
9. Celluzzi CM, Mayordomo JI, Storkus W, Lotze MT, Falo L. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-7.
10. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cell, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
11. Ossevoot MA, Feltamp M, van Veen K, Melief C, Kast WM. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother 1995;18:86-94.
12. Porgador A, Golboa E. Bone-marrow-generated dendritic cells pulsed with a class 1 -restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 1995:182:255-60.
13. Ribas A, Butterfield LH, McBride WH, et al. Genetic immunization for the melanoma antigen MART-l/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cane Res 1997;57:2865-9.
14. Wan Y, Bramson I, Carter R, Graham F, Gauldie J. Dendritic cells transduced with an adenoviral vector encoding a model tumor associated antigen for tumor vaccination. Hum Gene Ther 1997;8:1355-63.
15. Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
16. Sallusto F, and Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated tumor necrosis factor. J Exp Med 1994;179:1109-18.
17. Bakker ABH, Marland G, de Boer AI, et al. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cane Res 1995;55:5330-4.
18. Lansen JH, Wientjens GJHM, Fibbe WE, Willemze R, Kluin-Nelemans HC. Inhibition of human macrophage colony formation by interleukin 4. J Exp Med 1989;170:577-82.
19. Ruppert Friedrichs D, Xu H, Peters IH. IL-4 decreases the expression of the monocyte differentiation marker CD14, paralleled by an increasing accessory potency. Immimobiol 1991;182:449-64.
20. Mckenzie ANI, Culpepper J, de Waal Malefyt R, et al. Interleukin-13, a novel T cell derived cytokine that regulates human monocyte and B cell function. Proc Natl Acad Sei USA 1993;90:3735-9.
21. Doyle AG, Herbein G, Montaner LJ, et al. Interleukin-13 alters the activation state of murine macrophages in vitro: comparison with interleukin-4 and interferon. Eur J Immunol 1994;24:1441-5.
22. McKenzie ANJ, Zurawski G. Guidebook to cytokines and their receptors. New York: Oxford University Press, 1994.
23. Parham P, Brodsky FM. Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum Immunol 1981;3:277-99.
24. Anderson KS, Alexande J, Wei M, Cressewell P. Intracellular transport of class I MHC molecules in antigen processing mutant cell lines. J Immunol 1993;151:3407-19.
25. Morrison I, Elvin J, Latron F, et al. Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by CTL. Eur J Immunol 1992;22:903-8.
26. Kawakami Y, Eliyahu K, Sakaguchi PF, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-52.
27. Dedieu JF, Vigne E, Christophe T, et al. Long term gene delivery into the livers of immunocompetent mice with E1/E4 defective adenoviruses. J Virol 1997;71:4626-37.
28. Piemonti L, Bernasconi S, Luini W, et al. IL-13 supports differentiation of dendritic cells from circulating precursors in concert with GM-CSF. Eur Cytokine Netw 1995;6:245-52.
29. Arthur J, Butterfield LH, Roth MD, et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 1997;4:17-25.
30. Smith CA, Woodruff LS, Kitchingman GR, Rooney CM. Adenovirus-pulsed dendritic cells stimulated human virus-specific T cell responses in vitro. J Virol 1996;70:6733-40.
31. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997;3:483-90.